BJU Int

1. ZHAO K, Zhou Z, Dong Z
   Comment on 'Feasibility of randomisation to radical prostatectomy or standard care in patients with metastatic prostate cancer'.
   BJU Int. 2025 Nov 27. doi: 10.1111/bju.70097.
   

   >> Share

   
   
2. VAN DEN EYNDE L, Ost P, Lumen N
   Authors' reply to: comment on 'Feasibility of randomisation to radical prostatectomy or standard care in patients with metastatic prostate cancer'.
   BJU Int. 2025 Nov 27. doi: 10.1111/bju.70098.
   

   >> Share

   
   

   
   BMC Cancer

3. WAWRYK O, Collins IM, Lee A, Buzza M, et al
   Rural variations in primary care prostate cancer diagnosis and survival: a cohort study using linked Australian primary care electronic medical record data.
   BMC Cancer. 2025;25:1809.
   

   >> Share

   
   
4. ZHANG K, Wu K, Zhao C, Wang F, et al
   ACTC1 promotes tumor progression by upregulating BMP4 expression in prostate cancer.
   BMC Cancer. 2025 Nov 24. doi: 10.1186/s12885-025-15336.
   

   >> Share

   
   
5. DOZIE INS, Chukwuocha UM, Innocent DC, Dozie UW, et al
   A systematic review and meta-analysis of the prevalence and risk factors of prostate cancer in Nigeria.
   BMC Cancer. 2025 Nov 26. doi: 10.1186/s12885-025-15358.
   

   >> Share

   
   
6. KOCAK T, Acar-Tek N, Yesil S, Ergun MA, et al
   Could GSTP1, PTEN and NKX3.1 gene expression be novel markers in the relationship between prostate cancer and epigenetics?
   BMC Cancer. 2025;25:1825.
   

   >> Share

   
   

   
   BMC Urol

7. CHEN M, Zhou Y, Wang J, Qiu H, et al
   Correlation between metabolic unhealth and prostate cancer -an inverse probability weighting study.
   BMC Urol. 2025;25:295.
   

   >> Share

   
   

   
   Cancer

8. GRUTMAN AJ, Pavlovich CP
   The One Big Beautiful Bill Act and the future of prostate cancer care.
   Cancer. 2025;131:e70186.
   

   >> Share

   
   
9. KUMAR A, LaBella DA, Snider MC, Acklin-Wehnert SM, et al
   Prognostic significance of magnetic resonance imaging-detected extraprostatic extension in localized prostate cancer.
   Cancer. 2025;131:e70191.
   

   >> Share

   
   

   
   Eur J Radiol

10. SHEN S, Liu B, Li Y, Zeng Y, et al
    mpMRI-based interpretable machine learning model for predicting castration-resistant prostate cancer risk.
    Eur J Radiol. 2025;195:112521.
    

    >> Share

    
    

    
    Eur Radiol

11. FORREST AB, Kruse DE, Calio B, Ivey MC, et al
    Detection of clinically significant prostate cancer using targeted MRI-informed microultrasound biopsy.
    Eur Radiol. 2025 Nov 22. doi: 10.1007/s00330-025-12136.
    

    >> Share

    
    
12. YAN J, Jiang N, Wu S, Ren R, et al
    MRI evaluation of obturator internus muscle: its relationship with body composition and prognostic implications in prostate cancer patients undergoing ADT.
    Eur Radiol. 2025 Nov 27. doi: 10.1007/s00330-025-12156.
    

    >> Share

    
    

    
    Int J Radiat Oncol Biol Phys

13. DASSEN MG, Tree AC, Wiersema L, Neijndorff B, et al
    Primary endpoint analysis of the phase II DESTINATION-MRL trial for patients with intermediate-risk prostate cancer.
    Int J Radiat Oncol Biol Phys. 2025 Nov 26:S0360-3016(25)06502.
    

    >> Share

    
    
14. NABID A, Carrier N, Vigneault E, Martin AG, et al
    Impact of Persistent Hypogonadism on Overall Survival After Androgen Deprivation Therapy in Localized Prostate Cancer Patients: Long-Term Prospective Data.
    Int J Radiat Oncol Biol Phys. 2025 Nov 23:S0360-3016(25)06335.
    

    >> Share

    
    

    
    Int J Urol

15. SAKO S, Ito S, Ueda T, Gabata Y, et al
    DNA Methylation Levels at the C3orf37 Loci Correlate With Prostate Cancer Grade.
    Int J Urol. 2025 Nov 27. doi: 10.1111/iju.70299.
    

    >> Share

    
    
16. FANG D, Bi S, Wu L, Wang C, et al
    Preliminary Analysis of Prostate Cancer Screening Results and Exploration of Screening Model for Elderly Males in Rural Areas of Songjiang District, Shanghai.
    Int J Urol. 2025 Nov 21. doi: 10.1111/iju.70274.
    

    >> Share

    
    

    
    J Magn Reson Imaging

17. XU F, Zhang YD
    Editorial for "Development and Deployment of a Machine Learning Model to Triage the Use of Prostate MRI (ProMT-ML) in Patients With Suspected Prostate Cancer".
    J Magn Reson Imaging. 2025 Nov 22. doi: 10.1002/jmri.70190.
    

    >> Share

    
    

    
    J Nucl Med

18. BUCH-OLSEN KM, Vilstrup MH, Hansen S, Poulsen MH, et al
    Primary Staging of Intermediate- and High-Risk Prostate Cancer Using [(18)F]PSMA-1007 PET/CT and [(18)F]NaF PET/CT: A Head-to-Head Comparison of Diagnostic Accuracy, Staging, and Patient Management.
    J Nucl Med. 2025 Nov 25:jnumed.125.270710. doi: 10.2967/jnumed.125.270710.
    

    >> Share

    
    
19. GABLER N, Kirchhoff S, Sauter A, Heck M, et al
    [(18)F]Flotufolastat PET/MRI in Patients with Suspected Prostate Cancer: Correlation with Histopathologic Biopsy Results.
    J Nucl Med. 2025 Nov 25:jnumed.125.270435. doi: 10.2967/jnumed.125.270435.
    

    >> Share

    
    

    
    Lancet Oncol

20. THE LANCET ONCOLOGY
    Making prostate cancer screening fit for purpose.
    Lancet Oncol. 2025;26:1511.
    

    >> Share

    
    
21. ACHARD V, Blanchard P, Pasquier D, Sargos P, et al
    SBRT in oligometastatic castration-resistant prostate cancer.
    Lancet Oncol. 2025;26:e622.
    

    >> Share

    
    

    
    Nat Rev Urol

22. GUER M, Brisbane WG, Cash H, Ghai S, et al
    Micro-ultrasound for prostate cancer.
    Nat Rev Urol. 2025 Nov 27. doi: 10.1038/s41585-025-01111.
    

    >> Share

    
    

    
    Oncogene

23. NEPALI PR, Gonzalez-Kozlova E, Anegondi M, Dogra N, et al
    Effect of TGF-beta mediated phenotypic changes on prostate cancer cell anoikis response.
    Oncogene. 2025 Nov 22. doi: 10.1038/s41388-025-03600.
    

    >> Share

    
    
24. LI Y, Zhou Z, Zhang Y, Jia D, et al
    Targeting FZD6 creates therapeutically actionable vulnerabilities for advanced prostate cancer.
    Oncogene. 2025 Nov 24. doi: 10.1038/s41388-025-03631.
    

    >> Share

    
    

    
    Prostate

25. ILHAN Y, Araz M, Gurbuz AF, Urvay S, et al
    Prognostic Effect of KELIM Score of Prostate-Specific Antigen in Hormone-Sensitive Prostate Cancer Patients Treated With Novel Androgen Receptor Inhibitors: Pioneering New Ways.
    Prostate. 2025 Nov 23. doi: 10.1002/pros.70098.
    

    >> Share

    
    
26. ROMEI A, Orsatti C, Allegra AG, Nicosia L, et al
    Predictive Value of PSA Bounce Phenomenon after Stereotactic Body Radiation Therapy in a Large Population of Prostate Cancer Patients Treated By 1.5 T MR Guided Adaptive Technique.
    Prostate. 2025 Nov 28. doi: 10.1002/pros.70097.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share